Larimar Therapeutics, Inc. (LRMR) Stock Price & Analysis

Larimar Therapeutics, Inc. (LRMR) rose 0.00% to USD 3.83 as of September 8, 2026 at 04:59 UTC, according to Nexqual real-time market data.

LRMR last closed at USD 3.83; the session ranged USD 3.79–3.85 on volume of 391,990 shares. Market capitalization is $397.87M, with a 52-week range of USD 2.72–6.42 (NGM). Source: Nexqual, September 8, 2026 at 04:59 UTC.

Key Statistics (as of September 8, 2026 at 04:59 UTC)

Technical Analysis (LRMR)

Nexqual's technical model rates LRMR "SELL" based on 1 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 04:59 UTC.

Analyst Ratings (LRMR)

Wall Street analysts rate LRMR "None" based on 10 analysts, with a mean price target of USD 14.3 (range USD 5–26), per Nexqual as of September 8, 2026 at 04:59 UTC.

Earnings (LRMR)

Recent Earnings History

Source: Nexqual, September 8, 2026 at 04:59 UTC.

Financials & Fundamentals (LRMR)

Source: Nexqual, September 8, 2026 at 04:59 UTC.

Financial Health Score (LRMR)

Nexqual rates Larimar Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of September 8, 2026 at 04:59 UTC.

Ownership (LRMR)

Source: Nexqual, September 8, 2026 at 04:59 UTC.

Leadership (LRMR)

Larimar Therapeutics, Inc. is led by Carole S. Ben-Maimon (age 66), CEO, President & Director, per Nexqual as of September 8, 2026 at 04:59 UTC.

Major Backers & Investors (LRMR)

Notable institutional backers of Larimar Therapeutics, Inc. include Deerfield Management Company, L.P, Blue Owl Capital Holdings LP, Defilade Capital Management, L.P., according to Nexqual as of September 8, 2026 at 04:59 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, September 8, 2026 at 04:59 UTC.

From Larimar Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-19)

Key Strengths & Strategy (as disclosed to the SEC)

• We intend to use our proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.
• In June 2025, the FDA provided recommendations regarding the safety data that might be needed to support a Biologics License Application.("BLA") seeking accelerated approval, which included evaluating safety in at least 30 participants with continuous study drug exposure for six months and a subset of at least 10 of those participants with continuous study drug exposure for one year, with the large majority of data coming from participants receiving the 50 mg dose.
• As a result, we consulted experts and decided to modify the starting dose regimen 8   and the FDA agreed with our approach.
• Using our proprietary peptide delivery technology, nomlabofusp is designed to carry the molecule from the intravascular space across the cell membrane and into the mitochondria where the CPP and the mitochondrial targeting sequence are cleaved off by the mitochondrial processing peptidase ("MPP") enzyme to yield mature FXN.

Partnerships

• We are party to a Master Services Agreement with Lonza, pursuant to w h ich Lonza provides manufacturing services with respect to nomlabofusp.
• We may build our own internal sales force, partner with a contract sales organization, enter into a joint marketing partnership with another pharmaceutical or biotechnology company, or we may seek to out-license nomlabofusp. • Expand our product candidate pipeline to treat a variety of rare diseases.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 04:59 UTC. This page is informational and not investment advice.